Factors associated with nonadherence to antiretroviral therapy in people with HIV/AIDS

• Autores: Barrera-Espinoza, Richar William, Gómez-Gonzales, Walter Edgar, Girón-Vargas , Ana, Arana-Escobar, Magaly, Nieva-Villegas , Lilia María, Gamarra-Bustillos, Carlos, Auqui-Canchari, María, Zapana-Tito, María
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Universidad de San Martín de Porres
• Repositorio: Horizonte médico
• Lenguaje: español
• OAI Identifier: oai:horizontemedico.usmp.edu.pe:article/1498
• Enlace del recurso: https://www.horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1498
• Nivel de acceso: acceso abierto
• Materia: Adherencia al tratamiento; Terapia antirretroviral; VIH; Síndrome de inmunodeficiencia adquirida; Treatment adherence and compliance; Antiretroviral therapy; HIV; Acquired immunodeficiency síndrome

Objective: To determine the association that social, clinical and therapeutic factors and coexisting diseases have with nonadherence to antiretroviral therapy in people with HIV/AIDS in 2018. Materials and methods: A cross-sectional study conducted with a sample of 117 people with HIV/AIDS on antiretroviral therapy at the Hospital Daniel Alcides Carrión. The Questionnaire for the Assessment of Adherence to Antiretroviral Therapy (CEAT-VIH)adapted for use in Peru was administered. The IBM SPSS Statistics V23 and logistic regression were used for the statistical analysis. Results: Seventeen point one zero percent (17.10 %) of the patients did not adhere to the therapy and 82.90 % adhered to their prescribed treatment. The variables most likely to predict nonadherence were sex (OR = 16.175, p value = 0.023) and HIV/AIDSrelated comorbidities (OR = 9.556, p value = 0.003). The initial viral load variable (OR = 0.152, p value = 0.030) acts as a protector because there is a greater probability of treatment adherence. Conclusions: Male sex and HIV/AIDS-related comorbidities are associated with the nonadherence to antiretroviral therapy. The initial viral load variable acts as a protector for treatment adherence.